Pathological complete response in MMR-deficient/MSI-high and KRAS-mutant patient with locally advanced rectal cancer after neoadjuvant chemoradiation with immunotherapy: A case report
To date, preoperative chemoradiation (CRT) is the standard of care for patients with locally advanced rectal cancer (LARC) regardless of status of mismatch repair. Immunotherapy showed promising results in the neoadjuvant treatment trials in patients with mismatch repair-deficient (dMMR) or high mic...
Main Authors: | Mai Zhang, Hua Yang, Ling Chen, Kunli Du, Lina Zhao, Lichun Wei |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2022-09-01
|
Series: | Frontiers in Oncology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2022.926480/full |
Similar Items
-
Evaluation of Response and Toxicity in Patients with Locally Advanced Rectal Cancer Treated with Neoadjuvant Chemoradiation
by: Balaji Shewalkar, et al.
Published: (2023-07-01) -
Identification of Blood-Based Biomarkers for the Prediction of the Response to Neoadjuvant Chemoradiation in Rectal Cancer
by: Delphine Dayde, et al.
Published: (2021-07-01) -
Utility of rectoscopy in the assessment of response to neoadjuvant treatment for locally advanced rectal cancer
by: Victor Lopez-Lopez, et al.
Published: (2016-01-01) -
Predictors of tumor response to neoadjuvant chemoradiation in locally advanced rectal cancer Egyptian patients
by: Mohamed M. Elmessiry, et al.
Published: (2015-02-01) -
Genomic landscape of locally advanced rectal adenocarcinoma: Comparison between before and after neoadjuvant chemoradiation and effects of genetic biomarkers on clinical outcomes and tumor response
by: Tae Hoon Lee, et al.
Published: (2023-07-01)